Mendus publishes prospectus regarding previously announced rights issue and directed issue
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN…
News
electroCore Provides Select Second Quarter 2023 Financial Guidance
Record revenue of approximately $3,550,000 for the three months ended June 30, 2023; 65% increase…
electroCore Provides Select Second Quarter 2023 Financial Guidance
Record revenue of approximately $3,550,000 for the three months ended June 30, 2023; 65% increase…
TRACON Pharmaceuticals Announces Collection of Arbitration Award from I-Mab Biopharma
Collection of Award Extends Cash Runway into early 2024 and Past Expected Full Accrual of…
TRACON Pharmaceuticals Announces Collection of Arbitration Award from I-Mab Biopharma
Collection of Award Extends Cash Runway into early 2024 and Past Expected Full Accrual of…
Recce Pharmaceuticals Announces First Cohort Dosed in RECCE® 327 Rapid Infusion Phase I/II Urinary Tract Infection (UTI) Clinical Trial
Highlights: First cohort in Phase I/II urinary tract infection (UTI) rapid infusion intravenous (IV) study…
Recce Pharmaceuticals Announces First Cohort Dosed in RECCE® 327 Rapid Infusion Phase I/II Urinary Tract Infection (UTI) Clinical Trial
Highlights: First cohort in Phase I/II urinary tract infection (UTI) rapid infusion intravenous (IV) study…
Longeveron Appoints Dr. Nataliya Agafonova as Chief Medical Officer
Experienced Pharma Industry Clinical Operations Leader to Spearhead Development of Cellular Therapy Programs MIAMI, July…
Longeveron Appoints Dr. Nataliya Agafonova as Chief Medical Officer
Experienced Pharma Industry Clinical Operations Leader to Spearhead Development of Cellular Therapy Programs MIAMI, July…
Roivant Ranks No. 25 on Fast Company’s Fifth Annual List of the 100 Best Workplaces for Innovators and is the Winner on the Science and Technology List as a Part of the Best Workplaces for Innovators Program
Joining Adobe, Spotify, Nvidia, Morgan Stanley, and many others BASEL, Switzerland, LONDON, and NEW YORK,…
Synlogic Partners with Science 37 on Pivotal Study for Investigational Drug for Phenylketonuria (PKU)
Science 37’s Metasite to Facilitate Phase 3 Study Enrollment by Expanding Access and Maximizing Convenience for…
Roivant Ranks No. 25 on Fast Company’s Fifth Annual List of the 100 Best Workplaces for Innovators and is the Winner on the Science and Technology List as a Part of the Best Workplaces for Innovators Program
Joining Adobe, Spotify, Nvidia, Morgan Stanley, and many others BASEL, Switzerland, LONDON, and NEW YORK,…
Synlogic Partners with Science 37 on Pivotal Study for Investigational Drug for Phenylketonuria (PKU)
Science 37’s Metasite to Facilitate Phase 3 Study Enrollment by Expanding Access and Maximizing Convenience for…
Cognition Therapeutics Announces Dosing of First Patient in MAGNIFY Study of Oral CT1812 for Geographic Atrophy Secondary to Dry AMD
NEW YORK, July 11, 2023 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced that…
Cognition Therapeutics Announces Dosing of First Patient in MAGNIFY Study of Oral CT1812 for Geographic Atrophy Secondary to Dry AMD
NEW YORK, July 11, 2023 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced that…
Crossbow Therapeutics Launches with $80 Million in Series A Financing to Advance a Novel Class of Antibody Therapies That Mimic T-Cell Receptors to Treat Cancer
Proprietary T-Bolt™ technology dramatically broadens the benefits of immunotherapy by targeting the entire universe of cancer antigens …
Crossbow Therapeutics Launches with $80 Million in Series A Financing to Advance a Novel Class of Antibody Therapies That Mimic T-Cell Receptors to Treat Cancer
Proprietary T-Bolt™ technology dramatically broadens the benefits of immunotherapy by targeting the entire universe of cancer antigens …
Velocity and Privia Health Enter Partnership to Embed Clinical Research Into Practice Sites
Dr. Paul Evans, Chief Executive and President of Velocity Dr. Paul Evans, Chief Executive and…
ADC Therapeutics Announces Voluntary Pause of Enrollment in the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients
LAUSANNE, Switzerland, July 11, 2023 (GLOBE NEWSWIRE) — ADC Therapeutics SA (NYSE: ADCT) today announced…
Velocity and Privia Health Enter Partnership to Embed Clinical Research Into Practice Sites
Dr. Paul Evans, Chief Executive and President of Velocity Dr. Paul Evans, Chief Executive and…